Navigation Links
Analysis Shows BYDUREON™ Was Not Associated with Clinically Relevant QT Prolongation in Patients with Type 2 Diabetes: Results Presented at ADA 2011
Date:6/24/2011

ess release due to a number of risks and uncertainties, including the risk that the analysis mentioned in this press release may not be predictive; BYDUREON may not be approved by the FDA as soon as anticipated or at all; the companies' response to the FDA's complete response letter may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the QT study mentioned in this press release may not produce the results we expect; the FDA may request additional information prior to approval; BYETTA and/or the approval of BYDUREON and the revenues generated from these products may be affected by competition; unexpected new data; safety and technical issues; clinical trials not being completed in a timely manner, not confirming previous results, not being predictive of real world use or not achieving the intended clinical endpoints; label expansion requests or NDA filings not receiving regulatory approval; the commercial launch of BYDUREON being delayed; or manufacturing and supply issues. The potential for BYETTA and/or BYDUREON may also be affected by government and commercial reimbursement and pricing decisions, the pace of market acceptance, or scientific, regulatory and other issues and risks inherent in the development and commercialization of pharmaceutical products including those inherent in the collaboration with and dependence upon Amylin, Lilly and/or Alkermes. These and additional risks and uncertainties are described more fully in Amylin's, Lilly's and Alkermes' most recent SEC filings including their Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Amylin, Lilly and Alkermes undertake no duty to update these forward-looking statements.

BYDUREON™ and BYETTA® are trademarks of Amylin Pharmaceuticals, Inc. All other marks are the marks of their respective owners.

P-LLY

(i)  Long QT Syndrome. Heart Rhythm Society. Availab
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S.
2. Analysis Finds BYETTA® Associated with Lower Likelihood of Heart Failure Compared with Other Diabetes Therapies: Results Presented at ADA 2011
3. PRA Early Phase Leaders to Speak at Bioanalysis Forum
4. Dr. Assad Al-Ammar Joins Irvine Pharmaceutical Services as the New Minerals Analysis Manager in Response to the Growing Needs for USP Elemental Impurities Testing
5. Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries
6. Post Hoc Analysis from RECOVER Study Examined Effects of Neupro® (Rotigotine Transdermal System) on Surrogate Markers of Mood and Anhedonia in Parkinsons Disease
7. ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies
8. Hip Resurfacing Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
9. Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
10. Reportlinker Adds Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
11. Reportlinker Adds Hearing Aid Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), ... 3D bioprinting technology, announced today that Keith ... present live at VirtualInvestorConferences.com on March 5th. ... for this Company update," said Mr. Murphy. "We ... of the exVive3D Liver, Bioprinted Human Tissue, commercialization ...
(Date:2/27/2015)... 27, 2015  Bionik Laboratories Corp. (OTC:DWTPD), a ... that it acquired Bionik Laboratories, Inc., a ... sale to qualified accredited investors of units consisting of ... of approximately $6.2 million. Shares of the Company,s common ... Markets under the symbol "DWTPD" until FINRA,s approval of ...
(Date:2/26/2015)... 27, 2015  Finesse expands office in Leicester, ... the expansion of its operations in Leicester ... and access for customers is expected shortly afterward. ... adjacent to the current office, the new premises will ... and allow Finesse to bring on more service personnel. ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3New Finesse Office in United Kingdom 2
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... the International Symposium on Malignant Mesothelioma on Monday, March ... Hyatt Regency Bethesda in Bethesda, Maryland. The following award ... commitment to the mission to cure mesothelioma. , The ... presented to Miriam Ratner. Miriam runs the Meso Foundation’s ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
(Date:2/28/2015)... 2015 India Network Foundation, ... health insurance programs for visitors coming to the United ... parents traveling to the United States are suffering from ... blood pressure. These diseases are so common among the ... as medical conditions. There were 66.8 million cases of ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
Breaking Medicine News(10 mins):Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... five,disability income insurance claimants are satisfied with their ... Interactive on behalf of,America,s Health Insurance Plans (AHIP)., ... insurers are providing valuable income protection and,innovative services ... disabled,workers," said Karen Ignagni, President and CEO of ...
... developing a new type of glass that can dissolve and ... regrow bones and could signal a move away from bone ... is capable of acting as an active template for new ... of itself or any toxic chemicals. As it dissolves it ...
... ... offices, ... clinical software, connectivity and information,solutions that physicians use to improve healthcare, ... (EHR) and Practice Management (PM) solution for the 45 physicians,employed in ...
... June 5 Elekta, a world class leader ... to supply,multiple Elekta Synergy(R) digital linear accelerator systems ... few years., The new Elekta Synergy systems ... Therapy (IGRT), which Mary Bird Perkins,(MBP) began providing ...
... warns patients about injections on vacation whether ... June 5 The Physicians Coalition,for Injectable ... of the dangers of accepting Botox(R), Restylane(R) ... unfamiliar physicians during,vacation, cruise or spa encounters. ...
... chaired the committee that recently updated the ... Prevention and Treatment of Osteoporosis. The ... Organization (WHO) absolute fracture prediction algorithm (FRAX), ... identification of patients at risk for osteoporosis. ...
Cached Medicine News:Health News:Four Out of Five Disability Income Insurance Claimants are Satisfied With Their Policy 2Health News:Four Out of Five Disability Income Insurance Claimants are Satisfied With Their Policy 3Health News:A glass apart 2Health News:Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution 2Health News:Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution 3Health News:Rush-Copley Medical Center Selects Allscripts Electronic Health Record and Practice Management Solution 4Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 2Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 3Health News:Botox and Restylane Not A Destination or Spa Treatment 2Health News:Botox and Restylane Not A Destination or Spa Treatment 3Health News:Botox and Restylane Not A Destination or Spa Treatment 4Health News:Tufts researcher leads revision of osteoporosis guidelines 2Health News:Tufts researcher leads revision of osteoporosis guidelines 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: